At Leyden Labs, we're working to stop infections early by delivering antibody-based formulations directly to the nasal mucosa - eliminating the threat of respiratory viruses directly at the very gate through which they enter. The timing of this fundraising is critical - in light of recent avian flu (H5N1) developments, we feel even more urgency to execute our mission to protect people against existing and new viruses.
This strong support from investors validates our approach to providing broad, universal protection against current and future viral outbreaks.
Collection
[
|
...
]